The digital health platform will provide the infrastructure to support the conscious and trustworthy adoption of psychedelics DENVER, July 13, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company’), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced…


Previous articlePT253 – Sean Hinton Ph.D. – Culture, Research Limitations, and Non-Medical Paths Forward
Next articleWesana Health Announces Definitive Agreement to Acquire PsyTech Inc.